GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Total Operating Expense

CTNM (Contineum Therapeutics) Total Operating Expense : $38.62 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Total Operating Expense?

Contineum Therapeutics's Total Operating Expense for the three months ended in Jun. 2024 was $10.94 Mil. Contineum Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 was $38.62 Mil.


Contineum Therapeutics Total Operating Expense Historical Data

The historical data trend for Contineum Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Total Operating Expense Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Operating Expense
28.65 22.72 33.92

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Operating Expense Get a 7-Day Free Trial Premium Member Only 11.06 8.07 9.68 9.93 10.94

Contineum Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $38.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics Headlines

From GuruFocus